Skip to main content
Clinical Trials/NCT03795662
NCT03795662
Recruiting
Not Applicable

Surviving Pneumonia

Nordsjaellands Hospital1 site in 1 country2,500 target enrollmentJanuary 7, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Community-acquired Pneumonia
Sponsor
Nordsjaellands Hospital
Enrollment
2500
Locations
1
Primary Endpoint
Number of death from any causes
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

The study aims to explore risk factors for poor prognosis among patients admitted with community-acquired pneumonia (CAP). During a 5-year study period, all patients (aged ≥ 18 years) admitted with CAP at North Zealand Hospital will be invited for inclusion. Questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at admission, daily during admission, at discharge and at follow-up. The main clinical outcomes of the study consist of deaths and development of diabetes.

Registry
clinicaltrials.gov
Start Date
January 7, 2019
End Date
December 31, 2038
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Nordsjaellands Hospital
Responsible Party
Principal Investigator
Principal Investigator

Birgitte Lindegaard Madsen

Associated professor, MD, PhD

Nordsjaellands Hospital

Eligibility Criteria

Inclusion Criteria

  • Infiltrate on chest radiograph plus one or more of the following:
  • Fever (temperature, ≥38.0°C)
  • Hypothermia (\<35.0°C),
  • New cough with or without sputum production
  • Pleuritic chest pain
  • Altered breath sounds on auscultation.

Exclusion Criteria

  • Patients unable to give informed consent
  • Patients unwilling to give informed consent

Outcomes

Primary Outcomes

Number of death from any causes

Time Frame: From date of admission until the day of death from any causes, up to 24 months

Assessed through patient files

Number of participants who develop diabetes

Time Frame: Up to 24 months

Assessed through patient files and the national registers

Secondary Outcomes

  • Oral glucose tolerance test(Day 1, discharge (an average of 5 days), 1 month and 6-month)
  • Number of participants who are readmitted(Up to 6 months)
  • Length of hospital stay(Participants will be followed for the duration of hospital stay, an expected average of 5 days)

Study Sites (1)

Loading locations...

Similar Trials